2024/7/26 BIO Asia–Taiwan 2024 Exhibition Opens

 splicing errors in tumor cells to develop innovative therapeutic targets.

 

Thomas Evangelidis, Founder and CEO of AI/ffinity, discussed how his company uses protein NMR (nuclear magnetic resonance) data combined with AI for its drug discovery process. Shu-Chen Chen, Chief Scientific Officer of AnHorn Medicines, shared how AnHorn integrates AI into the drug design and discovery process to accelerate the development of innovative protein degradation drugs. NaHyun Kim, Solution Sales Specialist at Medidata, explained how Medidata's AI division applies AI and machine learning (AI/ML) technologies in clinical trials.

 

During the post-session discussion, Ching-Yung Lin mentioned that while AI has become extremely popular in the past five years, there is still much anticipation about whether AI will truly transform the pharmaceutical industry over the coming 20-30 years.

 

Session 12 focused was entitled ‘Advances in Genetics and Precision Medicine in Human Diseases’, and was chaired by Kang-Yuan Lee, Vice President of Taipei Medical University.

 

Toyomasa Katagiri, Director of Japan's National Institutes of Biomedical Innovation, Health and Nutrition, shared his team's development of a new mechanism for breast cancer therapy. John Jiang, Senior Director of Medical & Scientific Affairs at Illumina, discussed the application of genomic analysis in personalized cancer therapy. Kazuhiro Ito, Professor at Imperial College London, shared developments in precision respiratory medicine.

 

The post-discussion was chaired by Teh-Ying Chou, Vice Superintendent, Research and Development, Taipei Medical University Hospital. Sungmei Hsiung, Partner at DDT Attorneys-at-Law, specifically reminded technology developers to use patent tools to protect their research.

 

Held over lunch, Session 13, entitled ‘Shaping the Future of Digital Health,’ opened with talks by Chien-Cheng Tai, Senior Technical Specialist, Department of Industrial Technology, Ministry of Economic Affairs; and Eric Y. Chuang, Director of the Biomedical Technology and Device Research Laboratories (BDL), ITRI.

 

Nipun Jain, Director of AstraZeneca's Innovation and Partnerships, International Region, introduced the establishment of AstraZeneca's A.Catalyst Network, which is dedicated to promoting innovative therapies in Asia, East Asia, Africa, and Latin America. Tony Lee, Head of Sales, Google Cloud Taiwan, discussed various applications of Google AI in the healthcare field.

 

In the subsequent discussion, moderated by Chuang, the two speakers, along with Jing-Wei Lee, Superintendent, National Cheng Kung University Hospital; Kai-Cheng Hsu, Chief Medical Officer, Biomedical Big Data & Artificial Intelligence Technology, BDL, ITRI; and Peter Kurz, Chief Strategy Officer, QIC, explored strategies for promoting precision medicine through policies and public-private partnerships.